AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05249660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Instrument assisted soft tissue mobilization
Description: Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
Study NCT05264727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
Study NCT05264727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinisol 15%
Description: Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
Study NCT05663229 — intervention group
Intervention type: DEVICE
Intervention: Ankle foot orthosis
Description: We evaluate the difference of with or without ankle foot orthosis
Study NCT05484557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: treatment for 6 to 12 weeks
Study NCT05484557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium
Description: treatment for 6 to 12 weeks
Study NCT04913116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of antigen tests with RT-PCR as reference method
Description: Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
Study NCT05694611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
Study NCT05694611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
Study NCT05949892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Health Belief Model-Based Intervention
Description: A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
Study NCT05051228 — intervention group
Intervention type: DEVICE
Intervention: CardioFlux
Description: Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
Study NCT06560892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine injection
Description: patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
Study NCT06560892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05475002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care empowerment program
Description: dementia care e-books, dementia virtual reality activity and family support group
Study NCT05475002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dementia education
Description: dementia education manual and family support group
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo I-123 diagnostic scan
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-131 Uptake Test
Description: Undergo I-131 whole body scan
Study NCT06440850 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT06440850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Thyrotropin Alfa
Description: Given IM
Study NCT06440850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo neck ultrasound
Study NCT06440850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT05885126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MANDALA TECHNIQUE
Description: The ambient light and the position of the laptop table were adjusted appropriately during the intervention to help the participants move freely and eliminate the environmental stimulus. In addition, there was no communication between the patient and the practitioner during the application.
Study NCT04771273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide
Study NCT04771273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06529809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated external beam radiation
Description: Central pelvis (20 Gy in 10 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
Study NCT06529809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
Study NCT06529809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-guided brachytherapy
Description: HDR boost 7.3 Gy x 6 fractions
Study NCT06210893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The cricoid cartilage is located.
Description: The cricoid cartilage is located.
Study NCT06210893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The cricoid cartilage is located.
Description: The cricoid cartilage is located.
Study NCT06097338 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery (BS)
Description: bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
Study NCT05548309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
Study NCT05548309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen face mask
Description: Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
Study NCT05816720 — intervention group
Intervention type: DRUG
Intervention: Lutetium-177 DOTATATE
Description: Intravenous administration
Study NCT05122871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scape Room
Description: Practical training through scape-room with simulator
Study NCT05122871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation
Description: Practical training through simulator
Study NCT05099133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by injection just under the skin.
Study NCT05099133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 138559 Placebo
Description: LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
Study NCT04949386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1226 (8%)
Description: S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
Study NCT04949386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
Study NCT06599138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound-guided maxillary nerve block
Description: Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
Study NCT05626582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery - learning only
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
Study NCT05626582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery - learning and retention
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
Study NCT06679647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to a trained ChatGPT
Description: Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
Study NCT06679465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium (Spiriva®)
Description: 2 puffs tiotropium prior to allergen challenge
Study NCT06679465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs placebo
Study NCT06678802 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: blood sampling from peripheral vein
Study NCT06677801 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Telitacicept 160mg
Description: Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
Study NCT06679764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior quadratus lumborum block technique (AQLB)
Description: AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane.
Study NCT06679764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) block
Description: With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
Study NCT06679764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Pataints received opioid analgesia with genaral anesthesia
Study NCT06678477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D device
Description: Use 3D machine to generate the 3D image
Study NCT05096052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactomannan
Description: Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study NCT05096052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Study NCT06427824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)
Description: An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
Study NCT05292703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory activity based on art and olfactory stimulation
Description: practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
Study NCT05292703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: practicing art virtually in conjunction with olfactory identification
Description: For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks.
Study NCT04913090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet (for Part A)
Description: Tablet(s) administered orally once daily for 1 Day
Study NCT04913090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XZP-5610 Tablet (for Part A)
Description: Tablet(s) administered orally once daily for 1 Day
Study NCT04913090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5610 Tablet (for Part B)
Description: Tablet(s) administered orally once daily for 14 Days
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 5 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 6 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 7 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 8 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 9 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT05534945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus 10 ml
Description: patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain > 4/10
Study NCT04913090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match XZP-5610 Tablet (for Part B)
Description: Tablet(s) administered orally once daily for 14 Days
Study NCT06484140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Navigation
Description: During hospitalization, participants will receive needs assessment, and one-on-one cost-related health education with a material booklet. Resource and service referral will be delivered face-to-face or by phone when the navigator identifies unaddressed problems. Within three months after discharge, participants will receive monthly follow-up phone calls and personalized counseling via WeChat.
Study NCT06484140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
Study NCT06390488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous medial plantar nerve stimulation (T-MPNS)
Description: T-MPNS will be conducted unilaterally in the supine position using the electrotherapy device with surface electrodes. Two round self-adhesive electrodes will be positioned, with the negative electrode near the metatarsal-phalangeal joint of the great toe on the medial aspect of the foot and the positive electrode approximately 2 cm inferior-posterior to the medial malleolus (in front of the Medio-Malleolar-Calcaneal axis). Channel 1 will provide active stimulation, while channel 2 will remain inactive.
Study NCT06390488 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous medial plantar nerve stimulation (T-MPNS)
Description: Sham T-MPNS group will be stimulated using the same electrotherapy device, with patients positioned identically and electrodes placed in the same positions as in the T-MPNS group. The current characteristics (pulse frequency 20 Hz and pulse width 200 ms) will also remain consistent across both channels. The second channel of the stimulation device will be designated as the channel connected to the patient but without delivering stimulation.
Study NCT04913649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose 100 MG/ML
Description: Postoperative treatment with a single dose IVI (ferric derisomaltose), with a dose of 20mg/kg in approximately 60 minutes.
Study NCT04913649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Postoperative treatment with a single dose NaCl 0.9% in approximately 60 minutes.
Study NCT06056050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
Description: 1 dose of Tdcp vaccine (0.5ml) on Day 0